Stability studies-Regulatory evaluation & most frequently observed deficiencies-FDB experience Mercy Acquaye.

Slides:



Advertisements
Similar presentations
Dr. Birgit Schmauser, BfArM, Bonn
Advertisements

Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
1 The management and technical evaluation requirements of chemical drug substances State Food and Drug Administration Center for Drug Evaluation March.
Slide 1 of 30D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Slide 1 of 16 Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community Dar Es.
2-4 ICH Quality Guidances: an overview
API Stability Lynda Paleshnuik Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
CPH training | January |1 | Stability testing of Active pharmaceutical ingredients Hua YIN.
Finished Pharmaceutical Product Specifications
Stability data required by WHO-PQP Mercy Acquaye.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
Manufacturing Process
Batch Reworking and Reprocessing
World Health Organization
Stability testing of Finished Pharmaceutical Products
API Stability Testing WHO PQ Requirements Presented by Rutendo Kuwana Accra, Ghana December 2009.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
MANUFACTURING PROCESS AND VALIDATION
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pogány - Guilin 1/36 WHO Training Workshop on Pharmaceutical Quality, G MP and Bioequivalence with a focus on artemisinines János Pogány, pharmacist,
Inter-Laboratory Method Transfer
STABILITY STUDIES GABRIEL K. KADDU
Discussion on four presentations on Study design and statistical modeling for accelerated stability testing Regular long term stability – shelf life is.
World Health Organization
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 QIS/QOS: The new PQP quality templates.
Assessment experience
Dr. Pogány - WHO, Bangkok 1/71 QUALITY MANAGEMENT OF ANTIMALARIAL MEDICINES János Pogány, Ph.D., WHO consultant Bangkok, 19 October
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Slide 1 of 18D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Slide 1 WHO Prequalification Programme: Training workshop March 2010, Beijing Requirements on documentation of API and FPP quality and evaluation process.
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Stability Q1(R2). Role Of Stability Safety and efficacy of drug product are established during development via clinical studies Quality is established.
World Health Organization
World Health Organization
FPP Stability Lynda Paleshnuik Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Common Deficiencies in submissions for Prequalification (Quality part) HUA YIN Prequalification of Medicines Programme QSM / EMP / HSS WHO prequalification.
VALIDATION METHODOLOGY
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
1 2-2 FPP assessment: common deficiencies Wondiyfraw Worku 4 th Assessment training January 2012 Copenhagen.
PRODUCT TRANSFER.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Predicting Physical Stability in Q1A(R) Chi-wan Chen, Ph.D. Office of New Drug Chemistry Center for Drug Evaluation and Research Food and Drug Administration.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
Prequalification of Medicines Program
STABILITY TESTING Dr. Laila Khairy PhD, Chairman, NODCAR NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH Dr. Laila Khairy PhD, Chairman, NODCAR NATIONAL.
Stability Trials ASEAN Guidelines. The Objective of a stability study To determine the shelf life, namely the time period of storage at a specified condition.
Pharmaceutical Quality Control & current Good Manufacturing Practice PHT 436 Lecture 11 1.
Dr. Pogány - Geneva 1/30 PREQUALIFICATION OF ANTIMALARIAL DRUG PRODUCTS János Pogány, pharmacist, Ph.D. Geneva, 03 May 2004
Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Stability Studies : Regulatory evaluation and most frequently observed Sultan Ghani.
VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.
VICH Outreach Forum Stability Studies to address climatic zones III and IV Mai Huynh US FDA/Center for Veterinary Medicine October 26-27, 2015.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
David G. Donne, Ph.D. and Thomas J. DiFeo, Ph.D.
CAPA Central Administration of Pharmaceutical Affairs EDA The Egyptian Drug Authority NODCAR National Organization for Drug Control & Research The empowered.
Excipient Compatibility as Predicted by ASAP
STABILITY ?.
STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) & ASSIGNING RETEST PERIOD OF API’S January, 2015.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Dr. Birgit Schmauser, BfArM, Bonn
Name: Malcolm Dash Date: 26 October 2009
WHO Technical Report Series, No. 953, 2009
VICH Guidelines on stability: OVERVIEW
GL3 (R) – Stability Testing of New Veterinary Drug Substances and Medicinal Products (+ Annex GL 4 - Requirements for New Dosage Forms)
Quality guidelines on impurities
GL 51 – Statistical evaluation of stability data
GL8 (R) – Stability testing for medicated premixes
VICH Guidelines on stability: OVERVIEW
Presentation transcript:

Stability studies-Regulatory evaluation & most frequently observed deficiencies-FDB experience Mercy Acquaye

Failure to provide summary/evaluation of stability data Failure to use requisite number of batches Failure to use requisite batch size

Failure to test all stability-indicating quality parameters according to shelf life specifications of FPP Failure to provide details of the primary packaging materials Failure to provide the batch number of the API used for the FPP

Failure to provide a detailed description of the container/closure system including any liner or wadding Failure to make reference to end of shelf life specification numbers containing the description of validated stability indicating methods Failure to report on the accuracy and precision of the analytical method Failure to include a report of validation of test for impurities and degradants

Failure to provide stability protocol and stability testing commitment for on-going studies Failure to conduct studies at zone IVb climatic conditions of 30± 2 o C and 75 ±5%RH Failure to submit adequate minimum long term and accelerated stability data to justify regulatory shelf life of FPP

Thank you